

# International workshop on ALS: new genes, new treatments, new hopes

Madrid, October 30-31, 2019

## Scientific program:

Day #1: October 30, 2019			
9:00	<b>Opening</b>		
9:30	Orla Hardiman	Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland	Understanding the heterogeneity of ALS – A novel multimodal approach
10:15	Javier Riancho	Department of Neurology, Hospital Sierrallana-IDIVAL, Torrelavega, Spain	Environmental factors and amyotrophic lateral sclerosis
11:00	<b>Coffee-break</b>		
11:30	Adolfo López-Munain	Department of Neurology, University Hospital Donostia, Biodonostia Health Research Institute, CIBERNED, San Sebastián, Spain	Dissecting a metabolic hypothesis for amyotrophic lateral sclerosis
12:15	Markus Otto	Department of Neurology, University of Ulm, Ulm, Germany	Neurochemical markers for diagnosis, onset and prognosis of ALS
13:00	Alberto García-Redondo	Biochemistry Department, CIBERER U-723. Health Research Institute, October 12th Hospital, Madrid, Spain	Fine tuning a molecular diagnosis algorithm for patients with ALS and FTD
13:45	<b>Poster Session and Lunch</b>		
15:30	Adrian M Isaacs	Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK	C9orf72 ALS/FTD: molecular mechanisms
16:15	Emanuele Buratti	International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy	Using TDP-43-modifier genes to better understand pathology and explore therapeutic options
17:00	<b>Coffee-break</b>		
17:30	Caroline Rouaux	INSERM, UMR-S1118, University of Strasbourg, Strasbourg, France	Unravelling the molecular mechanisms behind corticospinal neuron degeneration in ALS

18:15	Robert H Baloh	Department of Neurology, Center for Neural Science and Medicine, Los Angeles, CA, USA	ALS genes that alter innate immune function and neuroinflammation
<b>Day #2: October 31, 2019</b>			
9:00	Rosario Osta	LAGENBIO, Veterinary Faculty, IIS Aragón, University of Zaragoza, CIBERNED, Zaragoza, Spain	The long road from preclinical trials to the patient: Insights from 20 years of research on SOD1G93A mice in LAGENBIO
9:45	Ana Martínez	Department of Chemical and Physical Biology , Centro de Investigaciones Biológicas (CIB)-CSIC, CIBERNED, Madrid, Spain	Protein kinase inhibitors as a new therapeutic approach for ALS
10:30	Ludo Van Den Bosch	KU Leuven - University of Leuven, Department of Neurosciences, Laboratory of Neurobiology and Experimental Neurology, Leuven, Belgium	Modulation of axonal transport as a therapeutic strategy in motor neuron diseases
11:15	<b>Coffee-break</b>		
11:45	Eva de Lago	Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, CIBERNED, Madrid, Spain	Targeting the CB <sub>2</sub> receptor to delay disease progression in ALS: studies in experimental models
12:30	Xavier Navarro	Institute of Neurosciences and Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, CIBERNED, Bellaterra, Spain	Gene therapy strategies for neuroprotection in ALS
13:15	<b>Poster Session and Lunch</b>		
15:00	Jeff D Rothstein	Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA	Disassembly and reassembly of the nuclear pore in C9 ALS/FTD and sporadic ALS: target for unique therapy
15:45	<b>Closing</b>		

